Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1938 1
1939 5
1940 1
1941 1
1942 1
1946 2
1947 3
1948 5
1949 2
1950 12
1951 13
1952 35
1953 21
1954 9
1955 12
1956 9
1957 22
1958 17
1959 21
1960 11
1961 13
1962 24
1963 47
1964 33
1965 40
1966 43
1967 40
1968 32
1969 40
1970 41
1971 40
1972 55
1973 60
1974 64
1975 62
1976 94
1977 84
1978 88
1979 125
1980 140
1981 169
1982 223
1983 209
1984 259
1985 294
1986 311
1987 383
1988 394
1989 428
1990 522
1991 574
1992 631
1993 752
1994 827
1995 980
1996 1115
1997 1328
1998 1482
1999 1834
2000 2160
2001 2498
2002 2988
2003 3491
2004 4169
2005 5046
2006 5803
2007 6345
2008 7425
2009 8175
2010 9255
2011 10531
2012 12079
2013 13235
2014 14839
2015 15973
2016 16982
2017 18139
2018 20194
2019 22977
2020 26629
2021 30219
2022 34526
2023 33805
2024 34912
2025 385

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

338,707 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Laixiao
Page 1
Did you mean li xiao lu (67 results)?
[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.
Hennrich U, Eder M. Hennrich U, et al. Pharmaceuticals (Basel). 2022 Oct 20;15(10):1292. doi: 10.3390/ph15101292. Pharmaceuticals (Basel). 2022. PMID: 36297404 Free PMC article. Review.
In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. ...In numerous clinical trials, the efficacy of [(177)Lu]Lu-PSMA-617 was demonstrated....
In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. ...I …
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2).
Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Bal C. Ballal S, et al. Pharmaceuticals (Basel). 2021 Nov 24;14(12):1212. doi: 10.3390/ph14121212. Pharmaceuticals (Basel). 2021. PMID: 34959613 Free PMC article.
The FAPi agents, [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2), were administered in two different groups of patients. ...In the [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2) group, the colon received the highest absorbed dose (right col …
The FAPi agents, [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2), were administered in two differen …
Preclinical Evaluation of (68)Ga- and (177)Lu-Labeled Integrin alpha(v)beta(6)-Targeting Radiotheranostic Peptides.
Ganguly T, Bauer N, Davis RA, Foster CC, Harris RE, Hausner SH, Roncali E, Tang SY, Sutcliffe JL. Ganguly T, et al. J Nucl Med. 2023 Apr;64(4):639-644. doi: 10.2967/jnumed.122.264749. Epub 2022 Oct 7. J Nucl Med. 2023. PMID: 36207137 Free article.
Biodistribution was performed for (68)Ga-1 (1 and 2 h after injection), (68)Ga-2 (2 and 4 h after injection), and (177)Lu-1 and (177)Lu-2 (1, 24, 48, and 72 h after injection). The (177)Lu-2 biodistribution data were extrapolated for human dosimetry data esti …
Biodistribution was performed for (68)Ga-1 (1 and 2 h after injection), (68)Ga-2 (2 and 4 h after injection), and (177)Lu-1 and (177) …
Prostate-Specific Membrane Antigen Radioligand Therapy Using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Schuchardt C, et al. J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887335 Free PMC article.
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I&T (0.77 vs. 0.92 Gy/GBq, P = 0.0015). ...No nephrotoxicity was observed after either (177)Lu-PSMA I&T or (177)Lu-PSMA …
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I …
Development of [(177)Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression.
Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T, Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X. Wen X, et al. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2846-2860. doi: 10.1007/s00259-023-06229-w. Epub 2023 Apr 25. Eur J Nucl Med Mol Imaging. 2023. PMID: 37097443
SPECT imaging of [(177)Lu]Lu-LNC1003 demonstrated significantly improved tumor uptake and retention as compared with [(177)Lu]Lu-EB-PSMA and [(177)Lu]Lu-PSMA-617, making it suitable for prostate cancer therapy. Biodistribution studies fur …
SPECT imaging of [(177)Lu]Lu-LNC1003 demonstrated significantly improved tumor uptake and retention as compared with [(177) …
Preclinical Characterization of DPI-4452: A (68)Ga/(177)Lu Theranostic Ligand for Carbonic Anhydrase IX.
Massière F, Wiedemann N, Borrego I, Hoehne A, Osterkamp F, Paschke M, Zboralski D, Schumann A, Bredenbeck A, Brichory F, Attinger A. Massière F, et al. J Nucl Med. 2024 May 1;65(5):761-767. doi: 10.2967/jnumed.123.266309. J Nucl Med. 2024. PMID: 38514083 Free PMC article.
In HT-29 and SK-RC-52 xenograft mouse models, both [(68)Ga]Ga-DPI-4452 and [(177)Lu]Lu-DPI-4452 showed tumor-selective uptake; in addition, [(177)Lu]Lu-DPI-4452 significantly reduced tumor growth. ...Conclusion: DPI-4452 selectively targets CAIX. [(68) …
In HT-29 and SK-RC-52 xenograft mouse models, both [(68)Ga]Ga-DPI-4452 and [(177)Lu]Lu-DPI-4452 showed tumor-selective uptake; …
Lutetium Lu 177 Dotatate.
[No authors listed] [No authors listed] 2020 Aug 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Aug 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000023 Free Books & Documents. Review.
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. No information is available on the use of lutetium Lu 177 dotatate during breastfeeding. The ma …
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroen …
Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection.
Verburg FA, de Blois E, Koolen S, Konijnenberg MW. Verburg FA, et al. EJNMMI Phys. 2023 Nov 10;10(1):69. doi: 10.1186/s40658-023-00589-w. EJNMMI Phys. 2023. PMID: 37947917 Free PMC article.
METHODS: Using established kinetic data for [(177)Lu]Lu-DOTA-TATE and [(177)Lu]Lu-PSMA-617, radiation absorbed doses to typical tumour lesion as well as non-target tissues ([(177)Lu]Lu-DOTA-TATE: kidneys, spleen and liver, [(177)Lu …
METHODS: Using established kinetic data for [(177)Lu]Lu-DOTA-TATE and [(177)Lu]Lu-PSMA-617, radiation absorbed d …
Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy.
Zha Z, Ploessl K, Choi SR, Zhao R, Jin W, Wang R, Alexoff D, Zhu L, Kung HF. Zha Z, et al. J Med Chem. 2023 Sep 14;66(17):12602-12613. doi: 10.1021/acs.jmedchem.3c01294. Epub 2023 Sep 5. J Med Chem. 2023. PMID: 37670407
Prostate-specific membrane antigen (PSMA) is an excellent target for imaging and radionuclide therapy of prostate cancer. Recently, [(177)Lu]Lu-PSMA-617 (Pluvicto) was approved by the FDA for radionuclide therapy. To develop hetero-bivalent agents targeting both PSM …
Prostate-specific membrane antigen (PSMA) is an excellent target for imaging and radionuclide therapy of prostate cancer. Recently, [(177) …
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, de Ridder C, Stuurman D, Konijnenberg MW, van Weerden WM, de Jong M, Nonnekens J. Ruigrok EAM, et al. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1339-1350. doi: 10.1007/s00259-020-05057-6. Epub 2020 Oct 23. Eur J Nucl Med Mol Imaging. 2021. PMID: 33094433 Free PMC article.
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lowest binding to these healthy organs compared with [(177)Lu]Lu-PSMA-I&T. ...CONCLUSION: [(177)Lu]Lu-PSMA-617 has th …
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lowest bi …
338,707 results
You have reached the last available page of results. Please see the User Guide for more information.